Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Other Non-Current Assets (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Other Non-Current Assets for 5 consecutive years, with $335000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $335000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $335000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $335000.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $335000.0 at Actinium Pharmaceuticals, up from $332000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $392000.0 in Q1 2021, with the low at $50000.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $281473.7, with a median of $313000.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Assets crashed 87.24% in 2022, then soared 508.0% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $50000.0 in 2021, then soared by 504.0% to $302000.0 in 2022, then increased by 3.64% to $313000.0 in 2023, then increased by 2.88% to $322000.0 in 2024, then grew by 4.04% to $335000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $335000.0, $332000.0, and $329000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.